Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GMED NYSE:HAE NYSE:INSP NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMEDGlobus Medical$77.81-8.5%$89.86$51.79▼$101.40$10.52B11.28 million shs6.04 million shsHAEHaemonetics$55.06+1.3%$59.53$47.31▼$87.32$2.56B0.53832,873 shs1.12 million shsINSPInspire Medical Systems$44.28-2.8%$56.01$43.99▼$161.88$1.28B0.831.23 million shs971,765 shsTNDMTandem Diabetes Care$15.48-16.2%$21.32$9.98▼$29.65$1.06B1.641.98 million shs7.53 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMEDGlobus Medical-4.76%-5.67%-5.52%-3.27%+18.80%HAEHaemonetics+3.65%-9.34%-8.46%-8.28%-15.21%INSPInspire Medical Systems-0.81%-18.75%-16.25%-30.86%-71.01%TNDMTandem Diabetes Care+2.44%-5.38%+1.04%-3.65%-17.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMEDGlobus Medical$77.81-8.5%$89.86$51.79▼$101.40$10.52B11.28 million shs6.04 million shsHAEHaemonetics$55.06+1.3%$59.53$47.31▼$87.32$2.56B0.53832,873 shs1.12 million shsINSPInspire Medical Systems$44.28-2.8%$56.01$43.99▼$161.88$1.28B0.831.23 million shs971,765 shsTNDMTandem Diabetes Care$15.48-16.2%$21.32$9.98▼$29.65$1.06B1.641.98 million shs7.53 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMEDGlobus Medical-4.76%-5.67%-5.52%-3.27%+18.80%HAEHaemonetics+3.65%-9.34%-8.46%-8.28%-15.21%INSPInspire Medical Systems-0.81%-18.75%-16.25%-30.86%-71.01%TNDMTandem Diabetes Care+2.44%-5.38%+1.04%-3.65%-17.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMEDGlobus Medical 2.81Moderate Buy$106.3636.70% UpsideHAEHaemonetics 2.73Moderate Buy$79.8945.09% UpsideINSPInspire Medical Systems 2.15Hold$85.0091.95% UpsideTNDMTandem Diabetes Care 2.55Moderate Buy$30.1694.82% UpsideCurrent Analyst Ratings BreakdownLatest INSP, HAE, GMED, and TNDM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026HAEHaemonetics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$67.005/8/2026GMEDGlobus Medical Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$104.00 ➝ $103.005/8/2026TNDMTandem Diabetes Care MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/8/2026GMEDGlobus Medical Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$115.00 ➝ $120.005/8/2026GMEDGlobus Medical Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$114.00 ➝ $117.005/8/2026HAEHaemonetics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$74.00 ➝ $62.005/7/2026INSPInspire Medical Systems OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform5/6/2026INSPInspire Medical Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/5/2026INSPInspire Medical Systems Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$56.00 ➝ $45.005/5/2026INSPInspire Medical Systems EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$55.005/5/2026INSPInspire Medical Systems Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$85.00 ➝ $55.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMEDGlobus Medical$2.94B3.58$5.48 per share14.20$33.86 per share2.30HAEHaemonetics$1.36B1.88$7.53 per share7.31$16.34 per share3.37INSPInspire Medical Systems$915.25M1.39$2.77 per share15.96$27.50 per share1.61TNDMTandem Diabetes Care$1.01B1.04N/AN/A$2.29 per share6.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMEDGlobus Medical$537.87M$3.9419.7515.942.0918.30%12.57%10.87%N/AHAEHaemonetics$167.68M$3.6315.1710.431.0313.31%27.32%9.61%N/AINSPInspire Medical Systems$145.42M$4.499.8623.314.7314.33%10.35%8.81%N/ATNDMTandem Diabetes Care-$204.71M-$3.07N/AN/AN/A-20.17%-68.23%-11.07%N/ALatest INSP, HAE, GMED, and TNDM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026GMEDGlobus Medical$0.92$1.12+$0.20$0.90$740.35 million$759.85 million5/7/2026Q4 2026HAEHaemonetics$1.28$1.29+$0.01-$0.44$336.83 million$346.35 million5/7/2026Q1 2026TNDMTandem Diabetes Care-$0.46-$0.30+$0.16-$0.30$240.41 million$247.22 million5/4/2026Q1 2026INSPInspire Medical Systems-$0.2753$0.10+$0.3753-$0.39$200.04 million$204.58 million2/24/2026Q4 2025GMEDGlobus Medical$1.06$1.28+$0.22$1.03$803.29 million$826.42 million2/19/2026Q4 2025TNDMTandem Diabetes Care-$0.05-$0.01+$0.04-$0.01$277.14 million$290.38 million2/11/2026Q4 2025INSPInspire Medical Systems$0.69$1.65+$0.96$4.66$264.02 million$269.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGMEDGlobus MedicalN/AN/AN/AN/AN/AHAEHaemoneticsN/AN/AN/AN/AN/AINSPInspire Medical SystemsN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMEDGlobus MedicalN/A4.262.74HAEHaemonetics1.011.751.15INSPInspire Medical SystemsN/A6.344.56TNDMTandem Diabetes Care2.002.552.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMEDGlobus Medical95.16%HAEHaemonetics99.67%INSPInspire Medical Systems94.91%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipGMEDGlobus Medical18.38%HAEHaemonetics1.84%INSPInspire Medical Systems2.20%TNDMTandem Diabetes Care2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMEDGlobus Medical6,000135.25 million110.39 millionOptionableHAEHaemonetics3,02346.47 million45.62 millionOptionableINSPInspire Medical Systems1,33328.81 million28.18 millionOptionableTNDMTandem Diabetes Care2,50068.50 million67.07 millionOptionableINSP, HAE, GMED, and TNDM HeadlinesRecent News About These CompaniesTandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up After Earnings BeatMay 8 at 10:10 AM | marketbeat.comTNDM Q1 deep dive: Margin expansion and pipeline advances amid business model shiftMay 8 at 8:54 AM | msn.comTandem Diabetes’s (NASDAQ:TNDM) Q1 CY2026: Beats On Revenue, Stock Jumps 10.9%May 8 at 8:54 AM | finance.yahoo.comBuy Rating Reaffirmed on Tandem Diabetes Care as Fundamentals Strengthen; $28 Price Target MaintainedMay 7 at 10:52 PM | tipranks.comTandem Diabetes Care (NASDAQ:TNDM) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPSMay 7 at 9:19 PM | marketbeat.comTandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue EstimatesMay 7 at 8:11 PM | zacks.comCompared to Estimates, Tandem Diabetes Care (TNDM) Q1 Earnings: A Look at Key MetricsMay 7 at 7:30 PM | zacks.comTandem Diabetes Care (TNDM) Stock Rises on Q1 2026 EarningsMay 7 at 5:30 PM | quiverquant.comQTandem Diabetes Care Announces First Quarter 2026 Financial ResultsMay 7 at 4:05 PM | businesswire.comTandem Diabetes (TNDM) Q1 earnings: What to expectMay 6 at 11:22 PM | msn.comHow Investors Are Reacting To Tandem Diabetes Care (TNDM) Expanding Control-IQ+ Use To Type 1 PregnanciesMay 2, 2026 | finance.yahoo.comJennison Associates LLC Purchases 601,260 Shares of Tandem Diabetes Care, Inc. $TNDMMay 2, 2026 | marketbeat.comTD Cowen Raises Tandem Diabetes (TNDM) Price Target, Keeps Buy RatingApril 30, 2026 | insidermonkey.comTandem Diabetes Care (TNDM) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comTandem Diabetes Care Announces Upcoming Conference PresentationsApril 29, 2026 | businesswire.comTandem Diabetes Care (NASDAQ:TNDM) Upgraded to "Strong-Buy" at Zacks ResearchApril 29, 2026 | marketbeat.comTandem Diabetes Care’s Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 DiabetesApril 28, 2026 | finance.yahoo.comFDA Flags High-Risk Recall For Tandem Diabetes Mobi PumpsApril 24, 2026 | benzinga.comTandem Diabetes Care, Inc. $TNDM Position Lowered by Paradice Investment Management LLCApril 24, 2026 | marketbeat.comKBC Group NV Lowers Holdings in Tandem Diabetes Care, Inc. $TNDMApril 23, 2026 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Hold" from BrokeragesApril 21, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026Churchill Downs: The Derby Is Just the BeginningBy Chris Markoch | April 24, 2026Palantir Drops After Anthropic Warning—Bull Case Remains Intact By Chris Markoch | April 14, 2026Palantir Drops After a Blowout Q1—What Investors Should KnowBy Chris Markoch | May 5, 2026INSP, HAE, GMED, and TNDM Company DescriptionsGlobus Medical NYSE:GMED$77.81 -7.26 (-8.54%) Closing price 03:59 PM EasternExtended Trading$78.81 +1.00 (+1.28%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Haemonetics NYSE:HAE$55.06 +0.69 (+1.27%) Closing price 03:59 PM EasternExtended Trading$54.77 -0.29 (-0.53%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Inspire Medical Systems NYSE:INSP$44.28 -1.29 (-2.83%) Closing price 03:58 PM EasternExtended Trading$44.26 -0.02 (-0.05%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Tandem Diabetes Care NASDAQ:TNDM$15.48 -2.99 (-16.19%) Closing price 04:00 PM EasternExtended Trading$15.64 +0.16 (+1.03%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
